No annual revenue total was found in PEPGEN INC.'s SEC filings.
Pepgen Inc. (PEPG) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$81.9 million. As of Jun 30, 2026 it held $117.2 million in cash and investments and $16.1 million in total debt.
Revenue
—
Net income (TTM)
$-71.94M
+25.8% vs year-ago TTM
Operating cash flow (TTM)
$-69.34M
+23.0% vs year-ago TTM
Free cash flow (TTM)
$-69.46M
+23.3% vs year-ago TTM
EPS (TTM)
$-1.19
+59.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
69.12M
+111.4% vs prior year
Net cash
$101.14M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PEPG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835597
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$93.6M | -$97.7M | -$84.8M | -$68.3M |
| Net income | -$89.7M | -$90.0M | -$78.6M | -$69.1M |
| Diluted EPS | -$2.12 | -$2.85 | -$3.30 | -$4.42 |
| Operating cash flow | -$81.6M | -$82.4M | -$69.0M | -$59.3M |
| Free cash flow | -$81.9M | -$82.9M | -$71.6M | -$63.0M |
| Total assets | $173.9M | $150.9M | $143.1M | $217.4M |
| Total liabilities | $26.5M | $32.3M | $34.6M | $37.8M |
| Stockholders' equity | $147.4M | $118.6M | $108.4M | $179.6M |
| Cash and investments | $148.5M | $120.2M | $110.4M | $181.8M |
| Total debt | $17.0M | $18.7M | $20.1M | $24.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 304 Pepgen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.